Curated news and analysis on clinical trials, drug approvals, and medical research.
MiniMed completed its $538 million IPO as its separation from Medtronic advances, with shares trading on the Nasdaq. Medtronic submitted the next-generation MiniMed Flex insulin pump to the FDA and reported a 14.8% year-over-year revenue increase for its Diabetes business. The full separation is expected to be complete by the end of calendar year 2026.
University of Florida researchers have established AI Replacement Dysfunction (AIRD), a new clinical model for recognizing and treating stress from AI-driven job insecurity. The framework, published in Cureus, outlines symptoms including anxiety, insomnia, and loss of identity, and proposes screening and treatment approaches for affected workers.
The FDA granted Rare Pediatric Disease designation to Atossa Therapeutics' (Z)-endoxifen for treating Duchenne Muscular Dystrophy. The designation may qualify the drug for a valuable Priority Review Voucher upon approval. Atossa reported a net loss of $34.8 million for 2025 as it advances clinical development.
Two Chinese pharmaceutical companies have reported new inhibitor discoveries in recent patents. Changchun Genescience Pharmaceuticals identified FGFR2/3 inhibitors for cancer and bone disorder treatment, while Hengrui Pharmaceuticals disclosed new SNF2L2 inhibitors potentially useful for cancer therapy.
CEL-SCI plans to start patient enrollment in summer 2026 for a 212-patient U.S. registration study of its cancer immunotherapy Multikine, with the goal of seeking early accelerated approval. The company is also advancing a strategic partnership with Saudi Amarox to commercialize Multikine in Saudi Arabia, where it has submitted a Breakthrough Medicine Designation application. These initiatives build on Phase 3 data showing Multikine improved 5-year survival in head and neck cancer patients from 45% to 73%.
A French cohort study found nirsevimab at birth reduces RSV-related hospitalizations in infants by 22% compared to maternal vaccination. UK data shows the maternal RSV vaccine provides over 80% protection when given at least four weeks before birth. Both strategies aim to protect vulnerable infants during their first months of life.
Updated KOMET-007 trial data show ziftomenib plus chemotherapy achieves 94% twelve-month overall survival in newly diagnosed NPM1-mutant AML. The oral menin inhibitor, approved by the FDA in November 2025 for relapsed/refractory disease, is being evaluated in a Japanese Phase II trial and a global Phase 3 study.
Kymera Therapeutics presented Phase 1 data for oral STAT6 degrader KT-621 in healthy Japanese adults, showing ≥98% STAT6 degradation and favorable safety. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected in 2027, and FDA has granted Fast Track designation for both indications.
Infrastructure Minister Chris Bishop announced fast-track approval for a 7.7km highway upgrade in the Western Bay of Plenty and a 2,800-home residential development in Queenstown. The Takitimu North Link Stage 2 highway project could generate $610 million in economic output, while the Queenstown housing project is estimated to contribute $720.3 million to GDP.
The FDA has cleared CStone Pharmaceuticals' investigational new drug application to begin a Phase II trial of its trispecific antibody CS2009 in advanced solid tumors. The multicenter trial will evaluate monotherapy and combination regimens across nine cancer types in Australia, China, and the U.S. Initial Phase I data showed a favorable safety profile and encouraging antitumor activity.
NeuroSense Therapeutics reported that its ALS drug PrimeC achieved a statistically significant 65% reduction in the risk of death in a Phase 2b trial. Separately, the company was granted a South Korean patent covering PrimeC's composition, formulation, and use for ALS treatment through 2042.
Personalized mRNA vaccines showed promise in pancreatic cancer trials with 7 of 16 patients in remission after five years. Stage 2 melanoma patients saw a 50% decreased death risk with personalized mRNA vaccines. U.S. funding cuts and policy shifts have stalled domestic mRNA cancer research while companies move trials abroad.
Colombian authorities confirmed the country's first uncrewed narco sub, a semi-autonomous vessel equipped with Starlink antennas and autopilot systems, was intercepted off Tayrona National Park. The discovery mirrors a broader trend of autonomous smuggling technology proliferating across the Pacific drug highway, where stealth vessels and narco-drones are outpacing enforcement capabilities.
New technologies enhance organoid screening for drug development, including a physics-informed deep learning framework for quantification and an automated electrophysiology system for functional analysis.
The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
Vaccine denial and weakened public health measures risk increasing chronic illness, as historical data shows post-infectious conditions follow major outbreaks. Long COVID affects 10-20% of those infected, while historical pandemics led to conditions like encephalitis lethargica with near 50% mortality.
Helus Pharma announced publication in Nature Medicine of Phase 2a trial results showing its short-acting psychedelic SPL026 met its primary endpoint with significant reductions in depressive symptoms at two weeks in moderate-to-severe MDD patients. The company also appointed a new SVP of Medical Affairs and is advancing HLP003 (Breakthrough Therapy Designation from FDA) and HLP004 in its pipeline.
Two securities class action lawsuits have been filed against NASDAQ-listed biopharmaceutical companies Ultragenyx and Vistagen. Both cases allege defendants made misleading statements about clinical trial results for key drug programs. Investors face deadlines in March and April 2026 to request lead plaintiff status.
Australia's Medical Research Future Fund is investing billions across multiple health research areas, including $100 million for arthritis research over 10 years, AU$22.9 million for dementia projects, and $436 million in 209 grants for Indigenous health research since 2017.
Takeda Pharmaceutical Company has announced updates on two ongoing neuroscience clinical trials: a Phase 2 study of TAK-360 for narcolepsy and a Phase 3 study of vortioxetine for major depressive disorder in Japanese teens. Both trials are randomized, triple-blind, and currently recruiting patients.
